Key takeaways
Foundayo is approved for weight management; Ozempic is approved for type 2 diabetes and cardiovascular risk reduction.
Foundayo is a daily pill; Ozempic is a weekly injection (with an oral option too).
Both work for weight and blood sugar and share similar side effects, but the right choice depends on your medical condition.
People often compare Foundayo (orforglipron) and Ozempic (semaglutide) because they are both GLP-1 drugs associated with weight loss. But they are not approved for the same uses. Foundayo is designated for weight loss, while Ozempic is primarily used for Type 2 diabetes, even though many people know it for its weight loss effects. The right choice depends on a person’s health history, treatment goals, insurance coverage, and whether a healthcare provider thinks either medication is appropriate. Below, we’ll break down the key differences between Foundayo and Ozempic.
Key differences
The biggest difference between Foundayo and Ozempic is their FDA-approved use. Foundayo is approved for chronic weight management, while Ozempic is approved for adults with Type 2 diabetes and to reduce certain cardiovascular risks in people with Type 2 diabetes. Although both medications can lead to weight loss, they are not interchangeable. Healthcare providers prescribe them for different primary purposes, based on a person’s diagnosis, health risks, and treatment goals.
Compare Foundayo vs. Ozempic key differences |
||
|---|---|---|
| Feature | Foundayo (orforglipron) | Ozempic (semaglutide) |
| Drug class | Non-peptide small-molecule GLP-1 receptor agonist | GLP-1 receptor agonist (peptide-based) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Active ingredient | Orforglipron | Semaglutide |
| FDA-approved indication | Obesity, or overweight with a weight-related medical condition | Type 2 diabetes, plus cardiovascular risk reduction in patients with T2D and established cardiovascular disease |
| Dosage form | Oral tablet (once daily) | Subcutaneous injection (once weekly) or oral tablet (once daily) |
| Food/dose timing restrictions | None | No food restrictions for the injection form, but the Ozempic pill should be taken on an empty stomach |
| Approved for weight loss? | Yes | No (Wegovy is the semaglutide brand approved for weight loss) |
Conditions treated
The most clinically significant difference is their approved use: Foundayo is approved for chronic weight management, while Ozempic is approved for Type 2 diabetes and cardiovascular risk reduction in certain patients. Both medications can help people lose weight, but that does not make them interchangeable.
“I would use Ozempic when I want a well-established option for patients with diabetes with strong A1C data. I would consider Foundayo in obesity management if access and cost make it easier, or if the patient prefers that specific oral option and it’s clinically appropriate,” says Paunel Vukasinov, MD, dual board-certified Internist and obesity medicine specialist with Medical Offices of Manhattan and contributor to Labfinder.com.
Their dosage forms differ because of their active ingredients. Foundayo contains orforglipron, a non-peptide GLP-1 medication that can be absorbed as a pill. Ozempic contains semaglutide, which is usually given as a once-weekly injection. Both help regulate blood sugar and appetite, but they’re taken in different ways.
There is limited head-to-head data comparing these medications. The closest comparison comes from ACHIEVE-3, a 52-week trial in adults with type 2 diabetes that compared orforglipron with oral semaglutide, not Ozempic’s injectable form. In that trial, the highest dose of orforglipron lowered A1C more than oral semaglutide and led to greater weight loss. Still, this doesn’t mean Foundayo and Ozempic are interchangeable, especially because they’re approved for different uses.
Compare Foundayo vs. Ozempic conditions treated |
||
|---|---|---|
| Indication | Foundayo | Ozempic |
| Chronic weight management (obesity) | FDA approved | Not approved; sometimes prescribed off-label (Wegovy is the semaglutide brand approved for weight loss) |
| Type 2 diabetes | Not approved | FDA approved |
| Cardiovascular risk reduction | Not approved | FDA approved (in adults with type 2 diabetes and established cardiovascular disease) |
How to take Foundayo
Foundayo is a once-daily oral tablet. It can be taken with or without food, but the tablet should be swallowed whole and not broken, crushed, or chewed. Do not take more than one tablet per day. If you miss a dose, take it as soon as possible, but do not take two doses in the same day. If you miss Foundayo for 7 or more days in a row, contact your healthcare provider about how to restart treatment.
“Foundayo is appealing for patients who strongly prefer an oral medication or really want to avoid injections,” says Fernando Ovalle Jr., MD, an obesity medicine specialist and contributor to Drugwatch.com. “Some patients are simply much more comfortable with a daily pill, and that matters because comfort and consistency affect adherence.”
According to Eli Lilly, Foundayo is started at 0.8 mg once daily. After at least 30 days, the dose is increased to 2.5 mg once daily, then to 5.5 mg once daily after at least another 30 days. From there, a healthcare provider may increase the dose to 9 mg, 14.5 mg, or 17.2 mg once daily, depending on treatment response and tolerability. The maximum dose is 17.2 mg once daily.
How to take Ozempic
Ozempic is a once-weekly subcutaneous injection that you’ll self-administer at home with a pre-filled pen. Ozempic injection is given under the skin of the abdomen, thigh, or upper arm using a prefilled pen. It should not be injected into a muscle or vein. Rotate the injection site each week to help reduce irritation. “Take it consistently on the same day each week,” Dr. Vukasinov says. “Eat smaller meals, avoid heavy/fatty foods, increase fiber, and hydrate well.” This advice can also apply to Foundayo.
Before first use, Ozempic pens should be stored in the refrigerator at 36°F to 46°F. After first use, they can be kept in the refrigerator or at room temperature for up to 56 days. The usual starting dose is 0.25 mg once weekly for 4 weeks, followed by 0.5 mg once weekly. If needed, a healthcare provider may increase the dose to 1 mg and then 2 mg once weekly.
Ozempic also comes as a pill, which you take daily, first thing in the morning, on an empty stomach. The starting dose is 1.5 mg, and it steps up to 4 mg after 30 days, then 9 mg after 30 more.
Foundayo vs. Ozempic weight loss results
This is a difficult comparison because Ozempic was not studied for weight loss in the same way Foundayo was. Ozempic was developed and approved for Type 2 diabetes, with weight loss observed as an additional effect rather than its primary treatment goal. Still, there’s some data in regard to its effect on weight. In its trials, Foundayo’s highest dose led to about 12.4% body weight loss. While Ozempic’s trial numbers run lower. That’s because those trials were measuring diabetes control, not weight.
Each manufacturer has also promoted research favoring its own medication. Eli Lilly announced a study where people on orforglipron lost an average of 14.6 lbs, versus about 11 lbs on oral semaglutide. Novo Nordisk countered with its own study, where oral semaglutide beat orforglipron in terms of weight loss. This trial used oral Wegovy, however, not Ozempic, since Wegovy is approved for weight management. These medications affect everyone differently. Anyone looking for a weight loss drug should talk to a healthcare provider about the best option for their situation.
Foundayo vs. Ozempic: Insurance coverage and cost comparison
Insurance coverage for Foundayo and Ozempic depends on your plan, diagnosis, and whether the medication is being used for an approved purpose.
Ozempic is more likely to be covered when prescribed for Type 2 diabetes. Many plans, including some Medicare Part D and Medicaid plans, may cover Ozempic injections or tablets for eligible patients with Type 2 diabetes, though prior authorization or step therapy may be required. Plans typically do not cover Ozempic when it is prescribed only for weight loss because that is an off-label use. Without insurance, the average retail price of Ozempic is about $1,393 for one 3 mL prefilled pen.
Foundayo coverage may be more limited because it is approved for chronic weight management. Some plans cover weight loss medications, while others exclude them or require documentation such as BMI, weight-related health conditions, or prior treatment attempts. Medicare generally does not cover medications used only for weight loss. Though eligible Part D beneficiaries may gain temporary access to certain GLP-1 medications through the Medicare GLP-1 Bridge. Without insurance, the average retail price of Foundayo is about $841 for 30 tablets of the 0.8 mg strength.
To check coverage, review your plan’s formulary or contact your insurance provider. You can also compare cash prices with a free SingleCare coupon, but coupons cannot be combined with insurance.
Compare Foundayo vs. Ozempic cost & coverage |
||
|---|---|---|
| Coverage details | Foundayo | Ozempic |
| Typically covered by insurance? | Varies by plan; some exclude weight loss medications | Usually, for approved uses |
| Typically covered by Medicare Part D? | Generally, no; the Medicare GLP-1 Bridge may provide temporary access | Yes, for approved uses |
| Typically covered by Medicaid? | Varies by state; often not covered | Usually for approved uses, but varies by state |
| SingleCare cost | $601.24 per 30, 0.8 mg tablets of brand-name Foundayo at Kroger | $791.97 per 3ml prefilled 2 mg/3 mL pen of brand-name Ozempic at Kroger |
| How to save with SingleCare | Get coupon | Get coupon |
Foundayo vs. Ozempic side effects
With either medication, be prepared for gastrointestinal side effects. They’re by far the most common. Foundayo’s clinical trials found the most frequent reactions were nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain.
Ozempic’s most common side effects are nearly identical: nausea, vomiting, diarrhea, abdominal pain, and constipation. Some 2026 research found that patients taking orforglipron were more likely to discontinue treatment due to side effects than those taking oral semaglutide. Though that trial wasn’t designed to compare tolerability, so it’s not a firm conclusion about which medication is easier to tolerate. There isn’t much direct comparison research yet.
Foundayo and Ozempic drug interactions and warnings
Foundayo may interact with medications that inhibit the enzyme CYP3A4, which breaks down orforglipron, such as itraconazole or clarithromycin. CYP3A4 inducers such as carbamazepine or rifampin can cause interactions as well. So can insulin or sulfonylureas such as glipizide and glimepiride, which affect blood sugar levels. Taking Foundayo with simvastatin (Zocor) may also cause a buildup of simvastatin in the body, raising the risk of side effects.
Ozempic can interact with insulin, sulfonylureas, and glinides, since all three raise the risk of low blood sugar. It may also interact with certain antibiotics (fluoroquinolones), which can affect blood sugar levels.
Because both medications slow gastric emptying, food takes longer to digest. This can curb appetite, but it also means certain oral medications, such as thyroid medications and birth control pills, may take longer to absorb.
Using GLP-1 medications while pregnant or breastfeeding is not recommended, since it’s unclear whether they could harm a fetus or newborn. GLP-1 medications also carry an FDA boxed warning for a risk of thyroid tumors, including medullary thyroid carcinoma (MTC). So if you or a family member has a history of thyroid cancer or Multiple Endocrine Neoplasia syndrome Type 2 (MEN 2), talk with a healthcare provider before taking either.
Dr. Ovalle says he also avoids prescribing either medication for patients with significant gastroparesis, severe reflux, recurrent pancreatitis, active gallbladder disease, severe dehydration risk, active eating disorders, and very restrictive eating patterns.
Which medication is right for you?
Their effects might look similar, but Foundayo and Ozempic are designed for different people. Only a healthcare provider can decide what is best for you. They’ll likely start with a simple question: What is your medical condition? If it’s Type 2 diabetes without obesity, Ozempic may be the preferred option. If it’s obesity without Type 2 diabetes, Foundayo is likely the better fit. If it’s both, either one could work. The best move is to leave the decision to a healthcare provider, who knows your health history, insurance coverage, other medications, and more.
Expert takeaway
“As a gastroenterologist, I see side effects of the GLP-1 medications quite often,” says Jesse P. Houghton, MD, senior medical director of gastroenterology at Southern Ohio Medical Center and member of the SingleCare Medical Review Board. “Nausea, vomiting, bloating, and constipation are the most common GI side effects of any of these medications. The key to their successful use is a thorough discussion with the patient regarding side effects prior to starting, along with a slow and gradual increase in their dosing.”
Frequently asked questions
Is Foundayo or Ozempic better for weight loss?
Foundayo. Not only is it FDA-approved for weight management, but research has suggested that patients may lose more weight on orforglipron than semaglutide, even though Ozempic is sometimes prescribed off-label for weight loss.
But for people who are seeking treatment for weight loss and not Type 2 diabetes, some clinical trials have suggested that oral Wegovy (also semaglutide) might be more effective than orforglipron.
What’s the main difference between Foundayo and Ozempic?
The primary difference is what they’re approved to treat. Foundayo is approved for weight management, while Ozempic is approved for Type 2 diabetes and cardiovascular risk reduction. Further, Foundayo’s active ingredient is orforglipron, and it comes in a once-daily pill, while Ozempic’s active ingredient is semaglutide, and it’s a weekly injection.
Can you take Ozempic for weight loss instead of Foundayo?
Technically, yes. You might be able to take Ozempic off-label for weight loss, particularly if you also have Type 2 diabetes. But you should only do so if your healthcare provider recommends it. Ozempic’s manufacturer, Novo Nordisk, also makes a semaglutide medication called Wegovy, which is FDA-approved for weight management.
The SingleCare prices in this article are the most accurate at the time of publishing in ZIP code 23666 as of Jul. 14, 2026. Prices vary by pharmacy. Visit our coupon page for updated drug prices at pharmacies near you.
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial, The Lancet (2026)
- Lilly’s oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial, Eli Lilly (2025)
- Foundayo label, DailyMed
- Ozempic label, DailyMed
- Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021)
- How to Take Foundayo, Eli Lilly
- The Ozempic once-weekly dosing schedule, Novo Nordisk
- What is Ozempic (semaglutide) Pill?, Novo Nordisk
- Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026, Novo Nordisk (2026)
- Medicare GLP-1 Bridge, Centers for Medicare & Medicaid Services (2026)
- Does Foundayo (orforglipron) interact with other medications?, Eli Lilly
- Warning letter Novo Nordisk Inc., Food and Drug Administration (2025)
- Medically accurate: SingleCare’s Medical Review Board analyzes all of our content to confirm it’s in line with current medical advice.
- Evidence-based: Our content is sourced from reputable U.S.-based healthcare professionals and peer-reviewed research.
- Trustworthy: All of SingleCare’s content goes through a multi-phase review process by our writers, editors, and Medical Board in order to provide clear and credible information.